SAMPLE APPEAL LETTER – FECAL CALPROTECTIN

Insurance Company

# RE: PATIENT

**DOB:**

**ID #**

**Pat Acct #**

DATE

Dear Sir, or Madam:

I am writing to request approval for fecal calprotectin for my patient, John Doe, whom I follow at the City Medical Center.

Mr. Doe has Crohn’s disease/ulcerative colitis and symptoms include [insert symptoms here]. The fecal calprotectin stool test will allow me to monitor his degree of inflammation and offer the opportunity to better predict the course of the disease, and make necessary treatment changes that will lead to symptomatic improvement, remission, and ultimately decrease the risk of hospitalization and need for surgical intervention. I request prior authorization to order the test, and have provided detailed medical information to support the change.

Roda, et al [[1]](#footnote-1) indicates that calprotectin is the best-characterized fecal marker of intestinal inflammation, and seems to represent a good predictor of relapse in patients affected by inflammatory bowel disease (IBD). Rosenfeld, et al 2 was the FOCUS trial (future of fecal calprotectin utility study in inflammatory bowel disease) that revealed results of fecal calprotectin changed management in the majority of patients affected by IBD. Calprotectin and other biomarkers are not only useful in predicting IBD activity, but they are also present in other gastrointestinal diseases. This stool test is helpful in detecting flares and in optimizing medical therapy. It will reduce unnecessary invasive testing like colonoscopy and MR/CT imaging.

I’m confident, given the benefits described, you will approve this request for calprotectin. Contact my office at (xxx) xxx-xxxx if any additional information will help clarify this request.

Sincerely,

Dr.

Contact Info

1. Roda G; Caponi A; Benevento M, et al. New Proteomic Approaches for Biomarker Discovery in Inflammatory Bowel Disease. *Inflamm Bowel Dis, Volume 16, Number 7, July 2010, 1239-1246*

   2 Rosenfeld G; Greenup A; Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. *World Journal of Gastroenterology, Volume 22, Number 36, September 2016, 8211-8218* [↑](#footnote-ref-1)